After years of capital investment, strive to make technological breakthrough and practical experience accumulation, R&D Center has established a professional systematical developing system, trains a young research team composed of over 230 PhDs, Masters and Bachelors, becomes the advanced novel drug continuing innovation center.
Based on characteristic of novel drug development and self-position, R&D Center set up Project development department, international co-operation department, No.1 generic drug research department, No.2 generic drug research department, No.3 generic drug research department, No.4 generic drug research department, No.5 generic drug research department, No.1 innovation drug research department, No.2 innovation drug research department, bio-drug research department, bio-evaluation research department, No.1 clinical research department, No.2 clinical research department, Sichuan register department, Beijing register department, pilot-scale department, manufacture coordinate department and general management department. Through the integration of new products’ chemical synthesis, pharmaceutical preparation, quality analysis, pharmacology and toxicology, clinical research, laws and regulations, R&D Center established efficient new project set up and policy decision system, project reward encourage system, quality control of R&D system, intellectual property protection system and personnel training system. Together, they promote the company innovation research on generic drug research, small molecular innovation drug research, mono-clone antibody research and international co-operation area.
Core R&D Team
Through the multi-level, multi-channel talent introduction and training, R&D Center has established a core research team composed with CSO, CTO, department manager, project manager who are expert on pharmaceutical chemistry, pharmacology, pharmacodynamics, clinical, quality control and policies and regulations.
>> CSO introduction:
Dr. PengCho Tang. In charge of the management of innovative drug R&D. Dr. Tang graduated from University of Chicago, major in Organic Chemistry and did Postdoc work in Columbia University. Then, he had successively held the posts of research Investigator in Hoffman La-Roche, Inc., Group leader in Glycomed, Inc., Senior Director in SUGEN, Inc., Senior Director in Hawaii Biotech, Inc.
Dr. Tang is the only scientist who had developed 14 clinical candidate compounds both in U.S and China, often been invited to give presentations and share his drug developing experience all over the world. After returned China, Dr. Tang held the post of CSO in Shanghai Hengrui Pharmaceutical. By using the resource in China, he built a world standard innovative drug research team from nothing and developed 7 clinical candidate compounds in different disease areas, applied over 40 patents. Famitinib and Retagliptin, which developed under Dr. Tang’s operation, have enter clinical phase 2 research and are hailed as sutent’s me-better and Sitagliptin’s best-in-class, respectively. Those drugs are expected to become the first-line medicine in gastric cancer, intestinal cancer and type 2 diabetes therapy. Dr. Tang has many publications in Authoritative publications, including 1 publication from J.Med.Chem and 4 from Bioorg Med.Chem.Lett in 2010. In addition, Dr. Tang is also the Member of Review Committee of Macau Science and Technology Development Fund and Adjunct Professor of Fudan University.
Based on abundant experience on drug development, Dr. Tang is focusing on building a research system with chemistry and biology hand-in-hand, rapidly improving Haisco’s innovative patent drug research level.